

**Amendments to the Claims:**

The following listing of claims replaces all prior versions and listings of the claims in this application.

**Listing of the Claims:**

1. (Cancelled).
2. (Withdrawn and Currently Amended) The method according to claim 21, transdermal drug delivery system for treatment of ophthalmic diseases according to claim 1, wherein the remedy for ophthalmic ~~disease~~ diseases is at least one agent selected from the group consisting of an antiviral agent, antibacterial agent, anti-mycotic agent, antiallergic agent, anti-inflammatory agent, nonsteroidal anti-inflammatory agent, anti-inflammatory-analgesic agent, anti-inflammatory enzymatic agent, antibiotic, sulfa agent, synthetic penicillin, remedy for glaucoma, remedy for cataract, miotic, mydriatic, topical astringent, vasopressor, preventive for rise in ocular tension, remedy for ocular hypertension, surface anesthetic,  $\alpha$ 1-blocker,  $\beta$ -blocker,  $\beta$ 1-blocker, carbonic anhydrase inhibitor, topical selective H1-blocker, adrenal cortical hormone, vitamin B12, coenzyme type vitamin B2, anticholinesterase agent, and ~~or~~ organic iodine preparation.
3. (Withdrawn and Currently Amended) The method according to claim 21, transdermal drug delivery system for treatment of ophthalmic diseases according to claim 1, wherein the remedy for ophthalmic ~~disease~~ diseases is at least one agent selected from the group consisting of an antibacterial agent, antiallergic agent, and ~~or~~ nonsteroidal anti-inflammatory agent.
4. (Withdrawn and Currently Amended) The method according to claim 21, transdermal drug delivery system for treatment of ophthalmic diseases according to claim 1,

wherein the remedy for ophthalmic disease ~~diseases~~ is a compound having a molecular weight of at most 1,000.

5. (Withdrawn and Currently Amended) The method according to claim 21,  
~~transdermal drug delivery system for treatment of ophthalmic diseases according to claim 1,~~  
wherein the remedy for ophthalmic disease ~~diseases~~ is an antibacterial agent, antiallergic  
agent or nonsteroidal anti-inflammatory agent having a molecular weight of at most 1,000.

6. (Withdrawn and Currently Amended) The method ~~transdermal drug delivery~~  
~~system for treatment of ophthalmic diseases~~ according to claim 5, wherein the remedy for  
ophthalmic disease ~~diseases~~ is ketotifen fumarate or diclofenac sodium.

7. (Cancelled).

8. (Withdrawn and Currently Amended) The method according to claim 21,  
~~transdermal drug delivery system for treatment of ophthalmic diseases according to claim 1,~~  
wherein the pressure-sensitive adhesive ~~layer~~ is a ~~pressure-sensitive adhesive layer~~ formed of  
a rubber-based pressure-sensitive adhesive, acrylic pressure-sensitive adhesive or silicone-  
based pressure-sensitive adhesive.

9. (Withdrawn and Currently Amended) The method ~~transdermal drug delivery~~  
~~system for treatment of ophthalmic diseases~~ according to claim 8, wherein the rubber-based  
pressure-sensitive adhesive comprises a styrene-isoprene-styrene block copolymer as a  
pressure-sensitive adhesive base.

10. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 8, wherein the acrylic pressure-sensitive adhesive is a (co)polymer of at least one alkyl (meth)acrylate, or a copolymer of an alkyl (meth)acrylate and a functional monomer or vinyl ester monomer copolymerizable with this ester or both monomers.

11. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 8, wherein the pressure-sensitive adhesive ~~layer~~ contains a percutaneous absorption enhancer.

12. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 11, wherein the percutaneous absorption enhancer is an aliphatic alcohol, fatty acid, fatty acid ester, alcohol amine, polyhydric alcohol alkyl ether, polyoxyethylene alkyl ether, glyceride, middle-chain fatty acid ester of a polyhydric alcohol, lactic acid alkyl ester, dibasic acid alkyl ester, acylated amino acid, pyrrolidone or its derivative, lactic acid, tartaric acid, 1,2,6-hexanetriol, benzyl alcohol, lanoline, potassium hydroxide (KOH), tris(hydroxymethyl)aminomethane, or a mixture of 2 or more compounds thereof.

13. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 11, wherein the percutaneous absorption enhancer is an aliphatic higher alcohol, fatty acid, alcohol amine, fatty acid ester, polyoxyethylene alkyl ether, KOH, tris(hydroxymethyl)aminomethane, or a mixture of two or more compounds thereof.

14. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 8, wherein the plaster layer comprises pressure-sensitive adhesive layer ~~is a rubber based pressure-sensitive adhesive layer containing~~ 100 parts by weight of the styrene-isoprene-styrene block copolymer, 10 to 400 parts by weight of a tackifier, 1 to 50 parts by weight of the percutaneous absorption enhancer and 0.1 to 60 parts by weight of the remedy for ophthalmic disease ~~diseases~~.

15. (Withdrawn and Currently Amended) The ~~method transdermal drug delivery system for treatment of ophthalmic diseases~~ according to claim 8, wherein the plaster layer comprises pressure-sensitive adhesive layer ~~is an acrylic pressure-sensitive adhesive layer containing~~ 100 parts by weight of the acrylic (co)polymer, 1 to 50 parts by weight of the percutaneous absorption enhancer and 0.1 to 60 parts by weight of the remedy for ophthalmic disease ~~diseases~~.

16. – 20. (Cancelled).

21. (New) A method for transferring a remedy for ophthalmic disease selected from the group consisting of ocular infection, allergic conjunctivitis, pollinosis and vernal conjunctivitis, to an external ophthalmic tissue comprising at least one of conjunctiva, lacrimal tissue and cornea, the method comprising applying a pressure-sensitive adhesive tape preparation comprising a plaster layer provided on a support, the plaster layer containing the remedy for ophthalmic disease and a pressure-sensitive adhesive, to a front skin surface of an upper eyelid and/or a lower eyelid to transfer the remedy for ophthalmic disease in the plaster layer to the external ophthalmic tissue by percutaneous permeation in such a manner that the remedy for ophthalmic disease is transferred by percutaneous permeation to the

external ophthalmic tissue from the skin surface, wherein the amount, in units of  $\mu\text{g/g}$ -tissue, of the remedy transferred by percutaneous permeation to the external ophthalmic tissue by the application within 8 hours after the application amounts to at least twice as much as the amount of the remedy transferred to the external ophthalmic tissue through a systemic blood flow.

22. (New) The method according to claim 21, wherein the amount, in units of  $\mu\text{g/g}$ -tissue, of the remedy transferred by percutaneous permeation to the external ophthalmic tissue by the application within 8 hours after the application amounts to at least five times as much as the amount of the remedy transferred to the external ophthalmic tissue through a systemic blood flow.